Ingeniatrics develops tailor-made nebulizer
About Ingeniatrics
Sunday, 13 April 2014 14:49
There are no translations available.

altalt

Ingeniatrics is specialized in fluid handling and the design and fabrication of nebulizers which are used in many areas.
Their nebulizers are highly appreciated in chemical analysis of Water (sea water, residues, processes, etc.) and other substances by ICP-OES and MP-AES (OneNeb). Furthermore they are used in treatment of residual water (lixiviates, pickles, etc.), evaporative cooling, humidification and microencapsulation of living cells microorganism (Cellena). These nebulizers are unique due to its protected IP technologies Flow Focusing® and Flow Blurring®.
Several prototypes for the creation of mean droplet diameter below 5 microns have been developed. These are for a unique application that requires a continual stream of nebulized droplets of a particular chemistry to affect the final overall process. Other nebulizers have been tested for that specific application but none of them offered the ability to dose the chemistry in a very small particle size in air.
Another prototype was developed for the production of particles between 0.8 and 1mm using viscous oily suspensions achieving liquid flow rates at 200Kg. per hour. The particles are generated with Flow Blurring® technology combined with electro-hydrodynamic forces. Every prototype delivery includes high standard quality control reports and a user guide, to assure correct handling of the final operators.
Ingeniatrics comprises professionals with experience in research and engineering, led by a managerial team that identifies with and is committed to the company’s strategic goal, and all are committed to their mission and values.
 
 
Ingeniatrics, partner of the 7th European Framework programme PneumoNP project, participates in the Kick off Meeting in San Sebastian, Spain on 28th 29th January 2014
About Ingeniatrics
Sunday, 13 April 2014 14:05
There are no translations available.

altaltalt 

PneumoNP’s 11 partners from 6 EU member states meet in San Sebastian, Spain on 28th/29th January 2014. PneumoNP is a European large research project funded under theSeventh Framework Programme (2014-2017) with a budget more than 5.5 M€.
Aiming to diagnose and treat antibiotic resistant pneumonia infections. Each partner has a distinctive role in the project, and brings its own expertise to the group. Ingeniatrics will be responsible for the creation of an optimal aerosol with the previous developed drug formulation with a defined droplet size and size distribution. Ingeniatrics know how in Drug Delivery and microencapsulation of high sensitive active pharmaceutical ingredients(API’s) will be beneficial for the whole development.
The main objective of the project is the development of a therapy and a diagnosis system for the treatment of lung infection (pneumonia). According to most of the international stakeholders from the healthcare sector, resistant Gram-negative bacteria are one of the major global health issues due to unavailable effective treatments. The PneumoNP team will focus its attention on infections caused by Klebsiella pneumoniae.
The application of nanotechnology to medicine always raises concerns among citizens, with good reasons. The incorporation of nanomaterials into the human body sometimes is a subject of reluctance. In PneumoNP all the existing safety and risk assessments will be strictly followed, especially all the recommendations generated by the European Commission. Dialogue about nanomedicine will be initiated with involved citizens (press relations, website, twitter…) through its dissemination activities. Finally, the project aims at showing that nanotherapy based drugs will reduce side effects, produce safer treatments and enable the use of biomolecule based drugs.
 
Furthermore PneumoNP will develop a new theragnostic system for a rapid identification of the bacteria strain causing the infection, and targeted treatment of the infected area with a selective therapeutic nanosystem.
 
Evonik´s 1st International Symposium on Solubility Enhancement
About Ingeniatrics
Tuesday, 29 October 2013 14:32

Evonik, Ingeniatrics´  business partner and one of the world's leading specialty chemicals companies with three reporting segments: Consumer, Health & Nutrition and Resource Efficiency and Specialty Materials, is holding the 1st International Symposium on Solubility Enhancement, taking place in Frankfurt, Germany.

This seminar will be an excellent opportunity  for lab managers and senior scientists from formulation development, scale-up, production or process development who have specific interest in solubility enhancement with EUDRAGIT® polymers and want to learn more about spray drying and melt extrusion.

María Flores, Ingeniatrics R&D Director, will be in the symposium as a guest speaker and industry expert, given a talk on the subject: “A novel convenient technology to generate core-shell particles”.

For more information and inscriptions, please follow the link:

http://eudragit.evonik.com/sites/dc/Downloadcenter/Evonik/Product/EUDRAGIT/Workshops/invitation---1st-international-symposium-on-solubility-enhancement.pdf

 
VII Forum on Industrial Applications of Nanotechnology (AIN)
About Ingeniatrics
Wednesday, 09 October 2013 07:15

Dr. Agustín Mariscal, Ingeniatrics´ CEO and Miriam Goldberg, Key Account Manager

The VII Forum on Industrial Applications of Nanotechnology, attended by companies specialize in Nanobiomedicine, Nanotechnology, Nanomaterials, Nanoscience , Biotechnology , Chemical, Consumer Goods Industry etc . , took place on October 1st, 2013, in La Casa Llotja de Mar , Barcelona , and was hold by the University Institute of Nanoscience of Aragon (INA ) .

Ingeniatrics was invited, as company expert in nano and microtechnology, to participate in one of the two round tables that took place that day, that one in Nanomedicine and Nanotechnology.


The forum discussion covered topics such as initial barriers found by research entities in order to transfer their technology to the industrial sector; facing the technology transfer stage, while protecting their patents and know-how; industry adaptation to be successful, given that it must adapt its facilities, equipment, working ways, etc.;  manufacture of biotechnology products and registration requirements in the pharmaceutical sector; current regulatory laws in Europe and in the United States, as an obstacle to the development of new products in nanomedicine , even having shown significant therapeutic efficacy;  difficulties that arise during scale production;  and personal experiences of the participating companies.

In the picture, from left to right, Dr. Scott Mitchell (BioNANOSurf), David Galán (FLUIDNATEK), Carlos Lurigados Delgado (BIOCAT), Dr. Agustín Mariscal (Ingeniatrics), Miriam Goldberg (Ingeniatrics) and Dr. Oscar P. Gulin (Argon Pharma).

 

 
"Building functional materials for health care and pharmacy from microfluidic principaples and Flow Focusing"
About Ingeniatrics
Monday, 09 September 2013 13:06

The publishing company Elservier has recently published the paper "Building functional materials for health care and pharmacy form microfluidic principles and Flow Focusing",  on the section of Advances Drug Delivery Reviews. As authors:

A.M. Gañán-Calvo, J.M. Montanero, L. Marín-Banderas, M. Flores-Mosquera.

Abstract:

In this review, we aim at establishing a relationship between the fundamentals of the microfluidics technologies used in the Pharmacy field, and the achievements accomplished by those technologies. We describe the main methods for manufacturing micrometer drops, bubbles, and capsules, as well as the corresponding underlying physical mechanisms. In this regard, the review intended to show non-specialist readers the dynamical processes which determine the success of microfluidics techniques. Flow Focusing (FF) is a droplet-based method widely used to produce different types of fluid entities on a continuous basis by applying an extensional coflow. We take this technique as an example to illustrate how microfluidics technologies for drug delivery are progressing from a deep understanding of the physics of fluids involved. Specifically, we describe the limitations of FF, and review novel methods which enhance its stability and robustness. In the last part of this paper, we review some of the accomplishments of microfluidics when it comes to drug manufacturing and delivery. Special attention is paid to the production of the microencapsulated form because this fluidic structure gathers the main functionalities sought for in Pharmacy. We also show how FF has been adapted to satisfy an ample variety of pharmaceutical requirements to date.

To read the hole paper an download it for free until January 2014, please click here.


 
TargetFish project counts on Ingeniatrics
About Ingeniatrics
Thursday, 04 July 2013 11:28


New and better vaccines to try to prevent disease outbreaks in farmed fish are the aims of a newly launched €6M research partnership. European aquaculture production provides work for around 65,000 people and has a turnover of € 3 billion. However infectious fish diseases can impact on plans to increase production and in some instances no effective treatments are available. The best method for disease control - both on economical and ethical grounds - is disease prevention by vaccination.

TargetFish brings together leading European research groups that are experts on the fish immune system and enterprises from the Biotech and Veterinary sectors to advance the development of existing (but not sufficient) and new prototype vaccines against socio-economically important viral or bacterial pathogens of Atlantic salmon, rainbow trout, common carp, sea bass, seabream and turbot. To achieve the challenging tasks, the project brings together 30 partners from 13 countries, amount them Ingeniatrics.

The role of Ingeniatrics, represented by our R&D director María Flores, is to participate in the microencapsulation of different fish vaccines for oral or immersion vaccination in alginate derivatives.

TargetFish is a large collaborative project funded by the European Commission under the 7th Framework Programme for Research and Technological Development. The estimated duration of the project is from october 2012 to september 2017.

To know more about this project, please click here

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 20